terça-feira, março 22, 2005
Gilead compra inibidor da integrase
Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor
Gilead Sciences, Inc. today announced that the company has entered into a licensing agreement with Japan Tobacco Inc. (JT), under which JT has granted to Gilead exclusive rights to develop and commercialize a novel HIV integrase inhibitor (JTK-303) in all countries of the world, excluding Japan, where JT will retain rights.
(...)
Integrase is one of the key enzymes required for HIV to replicate. By inhibiting this enzyme, the integration of HIV DNA into the DNA of immune system cells (the process by which infection occurs) is disabled. JT's compound has previously been evaluated in a Phase I study in Japan to assess bioavailability and pharmacokinetics in healthy volunteers. Gilead plans to initiate Phase I/II clinical studies in HIV-positive patients by mid-year.
Gilead and JT first partnered in July 2003, when the companies announced an agreement granting JT commercialization rights for Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine) in Japan.
